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Abstract
Background: Alpha interferon in combination with ribavirin is the standard therapy for hepatitis
C virus infection. Unfortunately, a significant number of patients fail to eradicate their infection with
this regimen. The mechanisms of IFN-resistance are unclear. The aim of this study was to
determine the contribution of host cell factors to the mechanisms of interferon resistance using
replicon cell lines.
Results: HCV replicons with high and low activation of the IFN-promoter were cultured for a
prolonged period of time in the presence of interferon-alpha (IFN-alpha2b). Stable replicon cell
lines with resistant phenotype were isolated and characterized by their ability to continue viral
replication in the presence of IFN-alpha. Interferon resistant cell colonies developed only in
replicons having lower activation of the IFN promoter and no resistant colonies arose from
replicons that exhibit higher activation of the IFN promoter. Individual cell clones were isolated
and nine IFN resistant cell lines were established. HCV RNA and protein levels in these cells were
not altered by IFN- alpha2b. Reduced signaling and IFN-resistant phenotype was found in all Huh-
7 cell lines even after eliminating HCV, suggesting that cellular factors are involved. Resistant
phenotype in the replicons is not due to lack of interferon receptor expression. All the cell lines
show defect in the JAK-STAT signaling and phosphorylation of STAT 1 and STAT 2 proteins were
strongly inhibited due to reduced expression of Tyk2 and Jak-1 protein.
Conclusion: This in vitro study provides evidence that altered expression of the Jak-Stat signaling
proteins can cause IFN resistance using HCV replicon cell clones.
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Background
Hepatitis C virus (HCV) is a blood-borne human patho-
gen. There are 170 million people worldwide infected
with HCV, representing a significant public health prob-
lem. Only a small fraction of individuals develop immu-
nity and clear virus infection naturally. The majority of
people exposed to HCV slowly develop into chronic infec-
tion. Long-standing chronic inflammation in the liver due
to the virus infection leads to liver cirrhosis and carci-
noma [1-7]. Infection with HCV is the leading cause of
liver transplantation in the United States [8]. Standard
therapy for chronic HCV infection is a combination of
IFN-α and ribavirin, but the majority of chronic hepatitis
C patients cannot clear their infection with this regimen.
Patients infected with genotype 1 HCV in the United
States are frequently resistant to IFN-α and ribavirin treat-
ment [9-13]. The reason why some chronic hepatitis C
patients do not respond to interferon therapy is unknown.
The HCV belongs to the family Flaviviridae. There are six
different genotypes of HCV distributed worldwide with
more than 50 subtypes [14,15]. There is 30% sequences
variation among each genotype, 15% among sub-types
and 1–5% among quasisspecies. The organization of HCV
RNA genome among all genotypes is similar. It begins
with a 5'untranslated region (UTR), long-open reading
frame and a 3' UTR region [16]. The HCV genome encodes
a large polyprotein of 3000 amino acids, which is proc-
essed into structural and non-structural protein in the
infected cells by viral and cellular proteases. Some reports
demonstrate that certain genotypes of HCV respond better
to interferon therapy compared than others. For an exam-
ple, 80% of chronic hepatitis C patients infected with gen-
otype 2 and 3 can clear the virus infection, while only 50%
in patients infected with genotype 1 [17,18] show a sus-
tained virological response. This clinical observation sug-
gests the involvement of viral factors in response to
interferon therapy. A number of molecular studies have
been performed with results suggesting that some of the
HCV structural and/or non-structural viral proteins block
the interferon induced antiviral pathways [19-26]. The
molecular basis of HCV resistance to interferon has
focused on NS5A and E2 protein action on the interferon
induced protein kinase R [27-31]. Recent studies also sug-
gest that the HCV protease (NS3/NS4A) can block the pro-
duction of endogenous of IFN-beta [32]. Most of the
studies of IFN resistance have focused on virus-related fac-
tors, and little attention has been paid to host factors. The
underlying mechanisms of interferon resistance against
chronic hepatitis C are not yet clear. The HCV RNA repli-
con systems have now proved to be a suitable model to
study the host-virus interaction. Understanding how viral
and host factors influence interferon sensitivity is impor-
tant as it may lead to the development of alternative strat-
egies to improve the success rate of interferon based
antiviral therapy.
Interferons are a family of cytokines that play a very
important role in innate immunity and protect humans
from infections with number of viruses and intracellular
organisms [33]. The interferon system is activated during
viral infection of a host cell, thus inhibiting virus replica-
tion during the host innate immune response. There are
two types of interferon. Type I interferon includes IFN-α
and interferon beta (IFN-β) and Type II interferon
includes interferon gamma (IFN-γ). Since endogenous
interferon produced by the infected cell is not sufficient to
eliminate the infection, exogenous recombinant human
IFN-α has been therefore used to treat chronic hepatitis C.
The cloning and sequencing of functional cDNAs for each
interferon has made it possible to use this cytokine as a
potential antiviral to treat number of virus infections [34].
The antiviral action of interferon is initiated when IFN-α
binds the receptor. Interferon binding to the cell surface
receptors activates the intracellular signaling pathways,
which involve Janus kinase (JAK1), tyrosine kinase 2
(TYK2) and signal transducer and activator of transcrip-
tion (STAT1 and STAT2) proteins. The JAKs phosphor-
ylate STAT proteins that either homo-or heterodimerize
and translocate to the nucleus thus inducing the expres-
sion of the IFN-stimulated genes (ISG). The phosphor-
ylated STAT1 and STAT2 combine with IRF-9 (interferon
regulatory factor 9) to form a trimeric ISGF-3 complex.
This complex enters the nucleus and binds to a consensus
DNA sequence [GAAAN(N)GAAA] called the interferon
stimulated response element (ISRE) [35,36]. This regula-
tory sequence is present upstream of most IFN-α and IFN-
β responsive genes. These cascades of molecular signaling
are essential for stimulation of interferon mediated gene
transcription. Previous studies in our laboratory suggest
that activation of interferon stimulated responsive ele-
ment (IFN-promoter) is critical in a successful antiviral
response against hepatitis C. This activation of interferon
induced gene activation via JAK-STAT pathways varies
among different Huh-7 clones [37].
This study was initiated to define the significance of IFN-
promoter activation in different replicon cell lines with
respect to the antiviral action of IFN-α2b. We found that
replicon cell lines with a low-level induction of interferon
promoter frequently develop resistance to IFN-α. In this
report, we have developed several stable replicon cell lines
in which replication of HCV is totally resistant to IFN-α.
The role of viral and cellular factors in the mechanisms of
IFN-resistance was examined. We showed here that the
altered expression of proteins in the Jak-Stat signaling
pathway of replicon cells block IFN-induced gene activa-
tion and cause interferon resistance.Virology Journal 2007, 4:89 http://www.virologyj.com/content/4/1/89
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Results
Isolation of interferon resistant HCV replicon cell lines
Previously, we reported data suggesting that activation of
this ISRE-promoter is important for a successful antiviral
action of IFN-α in replicon cells (37). It was observed that
the level of expression of luciferase from IRES promoter
by interferon varies among HCV replicon cell clones. To
understand the significance of this observation, we per-
formed the present study to determine whether the differ-
ences in the level of ISRE-promoter (IFN-promoter)
activation among different replicon cells are related to
interferon sensitivity. Three different replicon cell lines
showing lower ISRE promoter activation (Con-15, Con-
17 and Con-24) and three replicon cell line with higher
ISRE promoter activation (5–15, 9–13 and KR) were
treated with IFN-α2b (10–1000 IU/ml) and cultured in
the medium containing G-418 (1 mg/ml). All six replicon
cell lines used in our experiments have been prepared
using prototype Con1 sub-genomic replicon HCV RNA
(Fig. 1A). The HCV replicon is a dicistronic chimeric RNA
which contains the gene encoding for neomycin phos-
photransferase (conferring resistance to G-418) down-
stream of the HCV IRES. The second cistron in the same
RNA contains encephalomyocarditis virus IRES sequences
for efficient translation of HCV non-structural proteins
and this chimeric RNA terminates with the HCV 3'UTR.
This sub-genomic RNA replicates at a high level in Huh-7
cells and cell colonies develop that are resistant to G-418.
The ability of HCV sub-genomic RNA to replicate and
form G-418 cell colonies in the presence and absence of
IFN-α was examined. IFN-α efficiently inhibited HCV
RNA replication in three replicon cell lines with higher
activation of ISRE promoter and there were no viable cell
colonies are formed. However, antiviral action of inter-
feron against HCV was partially effective in the cell line
having lower activation of ISRE promoter since many vis-
ible clones were found (Fig. 2). The cell clones that sur-
vived interferon treatment grew well in the presence of
interferon alpha. Individual clones were picked and nine
different stable cell lines from each low inducer replicon
[Con-15 (15/1, 15/2, 15/3), Con-17 (17/1, 17/2, 17/3)
and Con-24 (24/1, 24/2, 24/3)] were prepared. The nine
different replicon cell lines were maintained in the pres-
ence of IFN-α2b (1000 IU/ml) for prolonged periods to
make sure that they are truly resistant to interferon.
Diagram of the sub-genomic replicon and reporter plasmid constructs used in the experiments Figure 1
Diagram of the sub-genomic replicon and reporter plasmid constructs used in the experiments. (A) The HCV 
replicon is a dicistronic chimeric RNA which contains the gene encoding for neomycin phosphotransferase downstream of the 
HCV IRES. The second cistern in the same RNA contains EMCV-IRES sequences for efficient translation of HCV non-structural 
proteins and this chimeric RNA terminates with the HCV 3'UTR. This sub-genomic clone has adaptive mutation S1179I that 
allows high level replication of RNA in Huh-7 cells and cell colonies develop that are resistant to neomycin. (B) pISRE-Luc 
reporter plasmid construct containing firefly luciferase reporter gene used to measure IFN-promoter activation in replicon cell 
lines. This construct has four copies of ISRE sequences positioned up stream of Herpes simplex virus thymidine kinase pro-
moter TATA box, which drives the expression of firefly luciferase. (C) Represents monocistronic reporter constructs that 
express green fluorescent protein translated by HCV IRES by using a T7 inducible system.Virology Journal 2007, 4:89 http://www.virologyj.com/content/4/1/89
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Characterization of HCV replicon cell lines
The antiviral effect of IFN-α against HCV in nine resistant-
replicon cell line was confirmed by measuring their ability
to form cell colonies in a medium containing G-418, sus-
tained viral RNA replication and protein expression. All
nine replicon cell lines were cultured in a medium con-
taining 1 mg/ml of G-418 in the presence of cyclosporine-
A or IFN-α. Their ability to form G-418 cell colonies was
measured in 100-mm tissue culture dishes. Results shown
in Fig. 3A, indicate that all resistant replicon cell lines
grew in the presence of IFN-α but not in the presence of
Cyclosporine-A. It is known that Cyclosporine-A inhibit
HCV RNA replication in Huh-7 cells by a different mech-
anism independent of Jak-Stat pathway. There is one
report documenting that replication efficiency depends
upon cell proliferation. To examine the possibility that
interferon resistance phenotype seen in the replicon cells
is due to certain growth advantage as compared to sensi-
tive cells, growth rate of nine different replicon cells were
over one week was compared to sensitive cell lines. No
significant differences in cell growth were observed
between nine different resistant cell lines and five differ-
ent sensitive cell lines.
To make sure that intracellular HCV RNA levels are stead-
ily maintained in the interferon treated cells, total RNA
was isolated from each replicon cell line and subjected to
RPA assay using probe targeted to the 5' UTR. Results of
this experiment (Fig 3B) indicated that the 296 nucleo-
tides protected band was detectable in all resistant cell
lines. There were no differences in the HCV RNA levels
between cells that were treated with or without interferon.
Intracellular HCV RNA levels in the nine different repli-
con cells were examined by RPA assay after Cyclosporine-
A treatment. The level of HCV protein expression was
compared between sensitive and resistant replicon cells
after interferon treatment by immunocytochemical stain-
ing using a monoclonal antibody to NS3 protein. Results
of this experiment are shown in (Fig. 3C) indicating all
resistant cells maintain high levels of viral protein expres-
sion after interferon treatment.
Isolation of HCV replicon cell lines possessing IFN-resistant phenotype Figure 2
Isolation of HCV replicon cell lines possessing IFN-resistant phenotype. Three stable replicon cell lines (Con-24, 
Con-17 and Con-15) having low ISRE-promoter activation and three replicon cell lines (9/13, 5/15 and KR) with high ISRE pro-
moter activation were treated with or without interferon alpha 2b (1000 IU/ml) for 4 weeks in a growth medium containing G-
418 (1 mg/ml). The ability of replicon cells to develop G-418 resistant cell colonies was examined. Cell colonies were devel-
oped only in low ISRE replicons. Three individual colonies from each dish were picked up and nine stable cell lines were gener-
ated.Virology Journal 2007, 4:89 http://www.virologyj.com/content/4/1/89
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Three panels showing HCV replication and protein expression in IFN resistant replicon cell lines Figure 3
Three panels showing HCV replication and protein expression in IFN resistant replicon cell lines. (A) Shows 
growth of nine different HCV replicon cell lines in medium containing 1 mg/ml G-418 in the presence of IFN-α2b. All cell lines 
grew and formed IFN-resistant cell colonies. Cyclosporin-A (1 mg/ml) inhibited the colony formation in the replicon cell lines 
in presence of G-418. (B) HCV replication is resistant to IFN-α2b treatment in nine different replicon cell lines. Stable cell lines 
were treated with or without IFN-α2b (1000 IU/ml) and cyclosporine-A (1 mg/ml) for a week. Intracellular HCV positive 
strand RNA was measured by RPA using an antisense riboprobe targeted to the 5'UTR. (C) Shows the effect of IFN-α2b on 
NS3 protein expression in interferon sensitive versus interferon resistant cell clones. Replicon cells in chamber slides were 
treated with IFN-α2b (1000 IU/ml) for a week, and immunostaining for NS3 protein was performed using a monoclonal anti-
body. IFN treatment abolished NS3 protein expression in sensitive cells (S-5/15). No inhibition was seen in any of these three 
resistant cell lines (R-Con-15, R-Con-17 and R-Con-24).Virology Journal 2007, 4:89 http://www.virologyj.com/content/4/1/89
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Interferon resistant replicons showed reduced IFN-
signaling
We reasoned there might be two possibilities that could
contribute to the IFN-resistant phenotypes in the cell cul-
ture models. First possibility is that sustained expression
of viral proteins directly block Jak-Stat signaling and make
cells insensitive to interferon. The second possibility is
that there may be a defect at the level of intracellular sign-
aling of interferon in these replicons. We have showed
earlier that IFN-α successfully inhibits translation and rep-
lication of full-length as well as sub-genomic HCV RNA in
Huh-7 cells suggesting that viral protein expression did
not inhibit interferon action. To clarify the role of cellular
contribution in the mechanism of IFN-resistance, HCV
replication was eliminated from each cell line by treat-
ment with Cyclosporine-A. The success of Cyclosporine-A
treatment and absence of HCV RNA in these cured cells
was confirmed by RPA and immunostaining for HCV NS3
protein. Cured cell lines were prepared from each resistant
replicon and cultured in regular growth medium without
G-418. Interferon signaling pathway in cured replicon
cells was examined using a construct pISRE-luciferase
reporter plasmid (Fig. 1B) in a transient transfection
assay. Results obtained from those experiments suggested
that luciferase activity in all the nine different replicon
cells were significantly low as compared to the interferon
sensitive cell lines (Fig. 4). The differences in the results of
luciferase expression from the ISRE promoter between
IFN-sensitive and IFN-resistant cells are found to be statis-
tically significant (p < 0.05).
We reported previously that interferon inhibits HCV rep-
lication by blocking at the level of viral IRES mediated
translation using a green fluorescence protein based sub-
genomic expression system [37,38]. Experiments were
performed to determine whether green fluorescence
expression from HCV IRES sub-genomic clone inhibited
by IFN-α in these cells. Nine different cured IFN-resistant
Huh-7 cell lines were transfected with HCV IRES-GFP
plasmid using a two-step transfection procedure described
in our previous publications. The cells were cultured in
the presence and absence of IFN-α (1000 IU/ml). The
IFN signaling in established replicon cell lines Figure 4
IFN signaling in established replicon cell lines. Each cured IFN resistant and sensitive cell lines were transfected with the 
pISRE-Luc plasmid. The activation of IFN promoter in the replicon cell lines was determined in the presence or absence of IFN-
α2b (1000 IU/ml) after 24 hours. All nine interferon resistant cell lines have lower activation of IFN-promoter as compared to 
interferon sensitive cell lines.Virology Journal 2007, 4:89 http://www.virologyj.com/content/4/1/89
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expression of green fluorescence between IFN-resistant
and sensitive cells was examined under a fluorescence
microscope. Results of these experiments indicate that
HCV IRES mediated translation is not sensitive to IFN-α
in all resistant Huh-7 cells (Fig. 5). Interferon effectively
inhibited expression of HCV IRES-GFP in all IFN-sensitive
clones. These results led us to conclude that these nine dif-
ferent cell lines that show interferon resistant phenotypes
have defects in the interferon signaling.
Defective Jak-Stat signaling in resistant replicons
We performed experiments to compare the level of expres-
sion of individual proteins of Jak-Stat pathways between
IFN-sensitive and IFN-resistant cells. Interferon first binds
to cell surface receptor that leads to activation of down
stream Jak-Stat signaling and activation of antiviral genes.
First we determined whether the interferon resistant phe-
notypes in these cells is due lack of expression of func-
tional interferon receptors on the cell surface. To test this
possibility, we performed a binding assay using 125I-
labeled interferon and nine different cured resistant cell
lines. The binding assay results were compared with a
cured interferon sensitive cell line to see the differences
(Fig. 6). It was observed that all resistant and sensitive
Huh-7 cells equally bind to 125I- IFN-α. The amounts of
125I-IFN bound (cpm) to the resistant cell line (15-1, 15-2
and 15-3) are comparable to sensitive cells (Fig. 6A). Sim-
ilar results were obtained with 17-1, 17-2 and 17-3 (Fig.
6B) and 24-1, 24-2, 24-3 (Fig 6C). The receptor binding
studies were also confirmed by examining expression of
interferon receptors using protein lysates by western blot
analysis (Fig. 7). Results of these experiments suggest that
the defect in the interferon signaling is not due to a lack of
cell surface expression of receptors.
We then examined whether there is an alteration in the
expression of down-stream signaling proteins that could
explain the cause of reduced IFN-signaling. Protein lysate
was made from three IFN-resistant cell lines (R-Con-15/1,
R-Con-17/1 and R-Con-24/1) (representative of each
series) and one sensitive replicon cell line. Equal amounts
of protein extracts were examined for the expression of
Jak-1, Tyk-2, Stat1, Stat 2 and Stat3 by Western blot anal-
ysis. The expression of unphosphorylated IFNAR1, Jak-1,
Tyk2, Stat1, Stat2 and Stat3 protein between IFN-sensitive
and IFN-resistant cells is shown in Fig. 7A. The results of
this experiment revealed that all resistant replicon cell
lines we developed have reduced expression of Tyk2 as
compared to the sensitive replicon cells. In some resistant
replicons expression of Jak-1 was also reduced. There were
no differences in the expression of Stat 1 and Stat 2 pro-
teins between sensitive and resistant cells.
Interferon treatment leads to tyrosine phosphorylation of
Stat 1 and Stat 2 protein followed by heterodimerization
of Stat1 and Stat 1. This dimer then enters the nucleus to
drive the transcription of antiviral genes. Therefore, phos-
porylation status of Stat1 and Stat 2 proteins between IFN-
sensitive and resistant replicon cells was examined using
phosphorylation specific commercially available antibod-
ies (Fig. 7B). It was observed that phosphorylation of
Stat1 and Stat2 was strongly inhibited in all interferon
resistant replicons as compared to the IFN-sensitive repli-
con. The differences seen in our analysis is not due to the
differences in the amount of proteins loaded into the gel
since beta-actin levels are found to be similar.
Discussion
Interferon alpha in combination with ribavirin is the
standard treatment for patients with chronic hepatitis C
virus infection. This therapy can eliminate virus infection
Interferon action on the IRES-mediated translational inhibition was prevented in cured resistant cell lines Figure 5
Interferon action on the IRES-mediated translational inhibition was prevented in cured resistant cell lines. 
Effect of interferon on IRES-GFP translation regulation was examined using one cured sensitive and nine resistant Huh-7 cell 
lines. Cells were transfected with IRES-GFP plasmid and treated with 1000 IU/ml interferon alpha. After 24 hours, GFP expres-
sion was recorded. Cured cells prepared from resistant clones unable to activate interferon signaling and no inhibition of HCV 
IRES was seen.Virology Journal 2007, 4:89 http://www.virologyj.com/content/4/1/89
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in approximately 80% of patients infected with genotype
2 or 3, and 50% in patients infected with genotype 1. The
reason why many patients infected with genotype 1 virus
fail to eradicate the virus is not clear. The mechanisms of
the resistance may be multifactorial. Several molecular
studies have been performed indicating that the viral fac-
tor plays a role in the persistent hepatitis C virus infection
and interferon resistance. Results of these studies indicate
that full-length as well as individual proteins of HCV
(NS5A, Core, NS3 and E2) block interferon action.
Among all the viral proteins studied the NS5A protein of
HCV has been proposed to be crucial for determining
interferon sensitivity. Chronic hepatitis C patients show-
ing amino acid substitution in the IFN-sensitivity deter-
mining region (2209–2248) of NS5A was found to have a
good response to interferon therapy. The role of ISDR
mutation and mechanisms of interferon resistance is not
yet conclusive. In contrast, clinical observations have sug-
gested that host factors may also play roles in IFN
response [39,40].
In this report, we used hepatic cell lines replicating sub-
genomic RNA since they represent similar to chronically
infected liver cells. Different laboratories including our
own have used the replicon based cell lines to test inter-
feron action against HCV replication. Results of all these
studies now suggest that interferon can successfully
inhibit replication of HCV sub-genomic RNA. Interferon
treatment activates a cascade of signal transduction path-
ways through its cell surface receptors that stimulate syn-
thesis of numerous antiviral genes. This signaling cascade
involves cell surface receptors, Janus kinase (Jak-1) and
tyrosine kinase 2 (Tyk-2) and signal transducer and activa-
tor of transcription (STAT1 and STAT2) proteins. The Jak-
1 and Tyk-2 phosphorylate the STAT proteins which either
homo-or heterodimerizes and then translocates to the
IFN receptor binding affinity between sensitive and resistant Huh-7 cell lines Figure 6
IFN receptor binding affinity between sensitive and resistant Huh-7 cell lines. Equal numbers of cured cells were 
incubated with different concentrations (3.9 to 125 ng) of 125I-IFN-α2b at 37°C for one hour. Non-specific binding was meas-
ured in presence of 100-fold excess of unlabeled IFN-α2b for each dilution. Cells were washed twice in PBS. Radioactivity 
(cpm) of each cell pellet was measured. The amount of interferon specifically bound was determined by subtracting non-spe-
cific binding from total binding. Specific binding of 125I-IFN-α2b to three groups of resistant cell lines and one sensitive cell line 
are shown (A-D).Virology Journal 2007, 4:89 http://www.virologyj.com/content/4/1/89
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nucleus and then binds to a consensus DNA sequence
called the interferon stimulated response element (ISRE).
This regulatory sequence is present upstream of most IFN-
α and IFN-β responsive genes. These cascades of molecu-
lar signaling are essential for the stimulation of interferon
mediated gene transcription. To support this notion we
previously showed that interferon alpha treatment acti-
vates the ISRE promoter driven transcription of luciferase
gene by transient transfection experiments and the path-
ways that leading to IFN-promoter activation also varies
among different replicon cell lines [37].
To understand the significance of IFN-promoter activa-
tion and interferon resistance in replicon cell lines, we
treated high and low inducer replicon cell lines with IFN-
α2b for a prolonged period of time with varied amount of
IFN starting from 10 IU to 1000 IU/ml. It was found that
cells that show a low level of IFN-promoter activation
could not eliminate HCV replication in all cells since
some Huh-7 clones develop resistance to interferon.
Using this approach, we developed interferon resistant
cell lines by treating low inducer replicon cells with alpha
interferons. We showed clearly that all these resistant rep-
licons have sustained viral replication that cannot be
inhibited by alpha interferon. The intracellular HCV RNA
levels and protein levels did not alter after interferon treat-
ment. We clarified that viral factors do not contribute to
the acquisition of IFN-resistance in these replicon cells
since the cured cells prepared from each replicon still
show reduced IFN signaling. Interferon signaling in the
cured cells was determined using a luciferase based
reporter assay. It was determined that there were no differ-
ences in the level of IFN-promoter activation in all resist-
ant cell lines with or without HCV replication. Based on
these evidences the role of virus contribution to the mech-
anisms of IFN-resistance in replicons was excluded.
Expression of GFP from HCV IRES was examined between
sensitive and resistant in the presence of interferon and
found that HCV IRES translation is not inhibited in resist-
ant Huh-7 cells. These results indicated that interferon
resistant phenotypes associated in our replicon cell line
might be due to a specific defect in the IFN-signaling path-
ways.
To identify the defect that is responsible for reduced inter-
feron signaling in these replicon cells, expression of Jak-
Stat proteins of interferon was examined. Interferon sign-
aling occurs through a series of protein-protein interac-
tions that initiate through a cell surface receptor
expression. We examined the expression of interferon
receptor expression by Western blot analysis as well as by
using receptor-binding assay. All the nine resistant cell
lines bind to iodinated IFN-α. It was determined that the
nature of the defect is not due to the lack of expression of
functional receptors on the cell surface. We then exam-
ined the expression of the down-stream signaling protein
of the Jak-Stat pathway between IFN-sensitive and resist-
ant replicons. An equal amount of protein lysates were
first tested for beta actin levels to exclude the possibility
that differences are not due to a lack of adequate amounts
of protein in the extracts. It was found that all resistant
Huh-7 cells have reduced expression of Tyk2. Reduced
expression of Jak-1 was also observed in some resistant
Huh-7 cells. The levels of Stat1 and Stat2 expression was
found be similar between resistant and sensitive repli-
cons. The phosphorylation of Stat1 and Stat2 proteins
were found to be strongly inhibited in all replicon cell
lines. Taken together our results suggest that the lack of
phophoryated STAT may be due to the reduced expression
of Jak-1 and Tyk2 in resistant replicons. Our data suggests
that the defect in Jak-Stat signaling can contribute to the
interferon resistant phenotypes.
While these studies are in progress, there are other labora-
tories also reported the development IFN-resistant repli-
Western blot analysis of the Jak-Stat signaling pathway in  IFN-sensitive and IFN-resistant cell lines Figure 7
Western blot analysis of the Jak-Stat signaling path-
way in IFN-sensitive and IFN-resistant cell lines. 
Three representative cured Huh-7 clones of IFN-resistant 
and one Huh-7 clone of IFN-sensitive cell line were treated 
with IFN-alpha (1000 IU/ml) for 30 minutes. Cell lysates 
were prepared and then equal amounts of protein lysates 
were used to examine the expression of IFN-receptor 
(IFNAR1), Jak-1, Tyk2, Stat 1, Stat 3 and Stat 3, phosphor-
ylated Stat 1 and Stat 2 by Western blot analysis. Beta actin 
levels were used, as a control to make sure that equal 
amount of protein was present in the extracts. All IFN-resist-
ant cell lines have reduced expression of Tyk2 and showed 
lack of Stat phosphorylation.Virology Journal 2007, 4:89 http://www.virologyj.com/content/4/1/89
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con cell lines. Studies by Sumpter et al [41] suggest that a
mutated replicon upon high passage develops resistance
to interferon. This suppression was due to a reduced acti-
vation of IFN-stimulated gene expression and blockage at
the viral IRES translation. Namba et al [42] developed an
IFN-resistant replicon by prolonged treatment with low
doses of IFN-α. These investigators have examined the
genetic alteration associated with the interferon resist-
ance. They found amino acid substitution in the NS4B
and several amino acid substitutions in the NS5A regions
suggesting that mutation in the viral sequence are
involved in the IFN-resistance. Subsequent studies by the
same group by Naka et al [43] reported that interferon
resistance in the replicon cells caused by functional dis-
ruption of type I interferon receptor gene (IFNAR1 and
IFNAR2c). Another study by Zhu et al [44] suggested that
mutation in the viral sequence is not responsible for inter-
feron resistance rather interferon resistance is due to a
defect in the Stat 3 activation. In this report the authors
did not notice any differences in the Stat1 and Stat2 phos-
phorylation. Our results suggest that a specific defect in
the expression of components in the Jak-Stat pathways
leads to defective Stat1 and Stat 2 phosphorylation.
Because of these defects, replicon cells are unable to trans-
mit signal to the nucleus and unable to induce antiviral
gene expression by interferon. The underlying mecha-
nisms of reduced expression of Tyk2 and Jak1 proteins in
these resistant cell clones are under investigation. We pro-
pose that examining the intracellular interferon signaling
pathways using IFN-sensitive and resistant hepatocytes
from chronically infected humans may provide critical
information regarding the mechanisms of interferon
resistance in the chronic hepatitis C.
Methods
Replicon Cells
Human hepatoma cell line Huh-7 cells were obtained
from the laboratory of James Wilson, Wistar Institute of
Human Gene Therapy, Pensylvania, grown in Dulbecco's
Modified Eagle's Medium (D-MEM), supplemented with
10% fetal bovine serum (FBS), non-essential amino acids
and sodium pyruvate. Stable replicon cell lines (Con-15,
Con-17, Con-24) were prepared in our laboratory as
described earlier [38]. Stable HCV replicon cell lines 5–15
and 9–13, replicating HCV subgenomic RNA were
obtained from the laboratory of Ralf Bartenschlager, Ger-
many. Another HCV replicon cell line (KR) was obtained
from George Liu, University of Kentucky. All replicons cell
lines were cultured in presence of G-418 (1 mg/ml, Genit-
icine, Invitrogen Life Technologies, Carlsbad, California,
USA).
IFN Treatment
Three different replicon cell lines (9–13, 5–15 and KR)
showing higher activation of interferon promoter and
three different replicon cell lines (Con-15, Con-17 and
Con-24) showing a low level activation of interferon pro-
moter were cultured in 100-mm culture dishes. All the
replicon cells were treated with human recombinant IFN-
α2b (10–1000 IU/ml) (Intron-A, Schering Plough Co.,
New Jersey, USA) in growth medium supplemented with
1 mg/ml G-418 in order to select cell colonies that are
truly resistant to interferon. Cultures were maintained for
more than two months with a regular medium change at
3 days until apparent IFN-resistant cell colonies devel-
oped on the culture plate. After 4 weeks of culture, IFN-
resistant cell clones were picked up and stable cell lines
were generated.
Replication assay
The ability of each of these replicon cell lines to resist the
antiviral action of interferon was examined by measuring
G-418 resistant cell colonies, sustained expression of viral
protein and replication of HCV RNA in the presence of
IFN-α2b. Both resistant and sensitive replicon cells were
cultured in 100-mm tissue culture dishes using a growth
medium containing 1 mg/ml G-418 with IFN-α2b (1000
IU/ml). The cells were maintained with a regular medium
change at every third day for a month in the presence of
interferon. The appearance of resistant cell colonies on the
tissue culture dishes was recorded. These results were
directly compared with interferon sensitive cell lines.
Ribonuclease Protection assay
To examine whether HCV-RNA replication in the replicon
cells was resistant to the antiviral action of interferon, cells
were cultured in the presence of IFN-α2b (1000 IU/ml).
Total RNA was isolated from the transfected cells after a
week by the GITC method. HCV positive strand RNA was
detected by a ribonuclease protection assay using an anti-
sense riboprobe targeted to the highly conserved 5' UTR
region. These results were directly compared with inter-
feron sensitive cell lines. The plasmid pCR II-296 was lin-
earized with Xba I and used to prepare an anti-sense RNA
probe using the SP6 RNA polymerase. For RPA assays,
approximately 1 × 106 cpm of the 32P-labeled anti-sense
probe was added to 25 μg of RNA sample and then vac-
uum dried. Hybridization was performed in 10 μl of the
hybridization buffer after denaturing for 3 minutes at
95°C and followed by overnight incubation at 45°C.
RNase digestion was performed in 200 μl of RNase cock-
tail (1: 100) (Ambion Inc. Austin, Texas) in a buffer con-
sisting of 10 mM Tris, pH 7.5, 5 mM EDTA and 0.3 M
NaCl for 1 hour at 37°C. Reactions were stopped by the
addition of 2.5 μl of 25% SDS and 10 μl of proteinase K
(10 mg/ml) at 37°C for 15 minutes. Samples were
extracted with phenol/chloroform and precipitated with
ethanol. The pellet was air dried and resuspended in 15 μl
of gel loading buffer. The samples were then boiled for 3
minutes and separated on an 8% acrylamide/8 M urea gel.Virology Journal 2007, 4:89 http://www.virologyj.com/content/4/1/89
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The gel was dried and exposed to X-ray film (Kodak, X-
OMAT-AR).
Viral protein expression
The level of viral NS3 protein expression in the resistant
cells was examined by an immunocytochemical method
using a monoclonal antibody. Replicon cells were immo-
bilized onto glass slides by cytospin method. Cells were
washed with phosphate-buffered saline (PBS) pH 7.4
twice, air-dried and fixed with chilled acetone for five
minutes. The cells were permeabilized by treatment with
0.05% saponin for 10 minutes at room temperature.
Blocking was performed with 5% normal goat serum
(Sigma Chemical Company, St. Louis, MO) diluted in
minimum essential medium for 30 minutes at room tem-
perature. Blocking for endogenous biotin-avidin was per-
formed using a commercially available kit (Avidin/Biotin
Blocking Kit, Vector Laboratories Inc., Burlingame, CA).
Blocking for endogenous peroxidase was carried out with
0.9% H2O2 for 30 minutes at room temperature. The cells
were incubated with monoclonal anti-NS3 antibody
(1:100 dilution) overnight at 4°C. The slide was then
washed three times and incubated with anti-mouse biotin
conjugated antibody (1:1000) for one hour at room tem-
perature. The slides were then washed and incubated for
30 minutes with Elite avidin-biotin peroxidase complex
(VECTOR Labs, CA). The slides were reacted with diami-
nobenzidine for 10 minutes. Counterstaining was per-
formed with hematoxylin for one minute. After
dehydration, the slides were mounted with permount and
observed by light microscopy.
Cyclosporin A treatment
Replication of sub-genomic HCV RNA in each replicon
cell line was eliminated after treatment with cyclosporin A
(1 mg/ml). Replicon cells were seeded in 100-mm plates
and treated with cyclosporine A (1 mg/ml) (Sigma Chem-
ical Co. St. Louis, Mo., USA) for one week in growth
medium without G-418. Presence or absence of HCV in
these cells was examined by expression of NS3 and viral
RNA by RPA. We selected cyclosporine A because this drug
inhibits HCV replication without any effect on the ISRE
promoter activity [37]. Interferon resistant phenotypes in
these cured cells were examined by measuring their ability
to activate interferon promoter and HCV IRES mediated
translation of GFP by the addition of exogenous IFN-
alpha2b.
Luciferase assay for IFN-β promoter
Regulation of ISRE-driven transcription of firefly luci-
ferase gene by IFN α was studied using IFN-sensitive and
IFN-resistant cell lines. Cells were transfected with 1 μg of
pISRE-luciferase plasmid (pISRE-Luc) (Fig. 1B) using the
FuGENE 6 transfection reagent (Roche Diagnostic Corpo-
ration, Indianapolis, Ind., USA). IFN-α2b (1000 IU/ml)
was added to the transfected cells to study its effect on
ISRE-mediated transcription of luciferase gene. To meas-
ure luciferase activity, cells were lyzed in a reporter lysis
buffer (Promega Corporation, Madison, Wisconsin, USA)
according to the manufacturer's instructions. The level of
expression in the replicons cell clones from the ISRE pro-
moter was carefully examined after correcting for the
amount of proteins in the lysates and the differences in
efficiencies of transfection. Luciferase activity was meas-
ured by integrating the total light emission over 10 sec
with a luminometer (Luman LB9507, EG&G Berthold,
Berlin, Germany). The results of RLU among transfected
cells were compared and values were expressed as fold
induction compared with the mock-transfected Huh-7
cells. All experiments were done in triplicates as described
previously [37].
HCV IRES-GFP translation
Interferon action on HCV IRES mediated translation of
green fluorescence protein was examined by using IFN-
sensitive and IFN-resistant cell clones. HCV IRES-GFP
expression in each cured Huh-7 cell line was performed
using two-step transfection procedures. Briefly, cells were
infected with 2 μl of the replication defective adenovirus
carrying the gene for T7 RNA polymerase. After 2 hours,
cells were transfected with 1 μg of pHCV-IRES-GFP plas-
mid (Fig. 1C) using FuGENE 6 transfection reagent
(Roche Diagnostic Corporation, Indianapolis, Ind., USA).
Immediately after, cells were incubated for 24 hours with
or without addition of IFN α-2b (1000 IU/ml). Cells were
counterstaining with DAPI (Calbiochem, San Diego, CA).
Expression of GFP in the transfected cell was examined
using a fluorescent microscope and composite picture was
generated by Adobe Photoshop computer software.
Western Blot Analysis
Cell lysates were prepared from replicon cells and exam-
ined for the expression of Jak-Stat signaling protein by
Western blot analysis. Antibodies for Jak-1, Tyk2, Stat 1,
Stat 2, Stat 3 proteins and phosphorylated Stat 1 and Stat
2 proteins were obtained from Cell Signaling Technology,
Beverly, MA. Antibody to interferon receptor was
obtained from R & D systems. Polyclonal antibody to
interferon receptor was obtained from Santa Cruz Labora-
tory. Antibody against beta actin was obtained from
Sigma Chemical Co, Saint Louis. Cured IFN-sensitive and
resistant replicons were treated with recombinant human
IFN-α (1000 IU/ml) for 30 minutes and Western blot
analysis for individual protein was performed using a
standard procedure of our laboratory [38].
IFN receptor binding assay
To determine whether interferon resistance phenotypes in
these resistant cells could have occurred due to lack of
expression or deletion of functional receptors. InterferonVirology Journal 2007, 4:89 http://www.virologyj.com/content/4/1/89
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binding to cell surface receptors was compared between
sensitive and resistant cells. For this purpose, IFN α-2b
(INTRON A, Schering Corporation) was labeled with 125I
using Iodobeads following the manufacturer's instruc-
tions (Pierce, Rockford, IL. USA) as previously described
[45,46]. Five micrograms of IFN-α were incubated with 10
μCi of NaI 125 (ICN Biochemicals) for 15 minutes. Free
and protein-bound 125I were separated by elution through
a prepacked Sepharose G-25 column (Pharmacia PD-10).
Peak fractions of radioactivity were pooled and the spe-
cific activity was determined (radioactivity associated with
per microgram of interferon). Binding experiments were
performed using a standard procedure described previ-
ously [45]. Hundred microliter of cured Huh-7 cells (105
cells) were incubated with six different concentrations of
125I-IFN α in 1.5 ml conical tubes and incubated for 60
minutes at 37°C. After centrifugation to 12000 rpm × 5
minutes cell the pellet was washed with 500 μl of PBS,
twice, and resuspended in 100 μl of PBS. The radioactivity
was detected by one minute in a gamma counter (LKB
Wallac-1282 Compugamma Universal Gamma Counter).
Nonspecific binding (NSB) was measured in presence of
100-fold excess of unlabelled IFN-α2b for each dilution.
The specific binding of interferon to Huh-7 cells at a dif-
ferent concentration was recorded. The amount of radio-
activity specifically bound to the cell surface at each
concentration of interferon was determined.
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